Radiotherapy in Li-Fraumeni Syndrome: Key Learning Points for Daily Practice

Based on the comprehensive Lancet Oncology review by Thariat et al. on Li-Fraumeni syndrome and radiotherapy, here is a blog post formatted for easy readability by radiation oncologists

Key take away points from the Article :

Thariat J, Chevalier F, Orbach D, Ollivier L, Marcy PY, Corradini N, Beddok A, Foray N, Bougeard G. Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes. Lancet Oncol. 2021 Dec;22(12):e562-e574. doi: 10.1016/S1470-2045(21)00425-3. PMID: 34856153.

Based on the comprehensive Lancet Oncology review by Thariat et al. on Li-Fraumeni syndrome and radiotherapy, here is a blog post formatted for easy readability by radiation oncologists:

---

Radiotherapy in Li-Fraumeni Syndrome: Key Learning Points for Daily Practice

What You Need to Know Right Now

Bottom Line: Patients with germline TP53 mutations carry a dramatically elevated risk of second malignant neoplasms (SMNs) after radiotherapy. The decision to irradiate requires a delicate risk-benefit calculation involving a multidisciplinary team.

---

1. Understand the Two Types of Risk in TP53-Mutated Patients

Radiosusceptibility (Risk of Second Cancers)

• The real problem in Li-Fraumeni syndrome
• Dysfunctional p53 leads to misrepaired DNA breaks
• Results in radiation-induced second malignancies years after treatment
• Can occur at low doses (even <5 Gy)

Radiosensitivity (Acute Toxicity)

• Good news: Similar to the general population
• Normal tissue toxicity is NOT increased
• Use standard dose constraints

Clinical Pearl: Don't confuse these terms. Many TP53 patients tolerate radiotherapy acutely but develop cancers years later.

---

2. Know When to AVOID Radiotherapy

Scenario	Recommendation
Breast cancer (in-situ)	Mastectomy + reconstruction (avoid RT)
Prostate cancer (low-risk)	Active surveillance or surgery (avoid RT)
Benign tumors	Surgery only; RT as last resort
Stage I lung cancer (operable)	Surgery preferred

Rule: If another equally curative option exists (surgery, brachytherapy, active surveillance), radiotherapy should be avoided.

---

3. When Radiotherapy IS Necessary: Choose the Right Technique

Photon Techniques (Ranked by Preference)

Option 1: 3D Conformal Radiotherapy

• Simple, standard technique
• Acceptable low-dose spillage
• Lower cost
• Use this if proton therapy unavailable

Option 2: Intensity-Modulated Radiotherapy (IMRT)

• Better conformality for the tumor
• BUT: Higher low-dose bath to surrounding tissues (2-10 Gy range)
• May increase SMN risk
• Only use if 3D cannot achieve adequate coverage

Avoid: High-energy photons (15-18 MV) → produce neutrons → extra dose to distant tissues

Particle Therapy: First Choice When Available

Proton Therapy

• ✅ Recommended in Li-Fraumeni syndrome
• Reduces irradiated volumes 2-fold vs. photons
• Lower scattered dose to normal tissues
• No low-dose bath beyond Bragg peak
• Risk of SMN reduced by factor of 2-10

Carbon Ions

• ❌ NOT recommended for TP53-mutated patients
• Higher linear energy transfer may cause complex DNA damage that's harder to repair
• Increased sarcoma risk in preclinical studies

---

4. Dose and Fractionation

Key Principles

Parameter	Recommendation
Tumor dose	Standard (do NOT reduce—tumors are NOT radioresistant)
Normal tissue dose	Minimize through superior targeting
Fractionation	Standard (no evidence for hypofractionation benefit)
Fraction size	Standard 1.8-2 Gy/fx (no protection from smaller fractions)

Clinical Pearl: The dose-response relationship for SMNs is linear at low doses. Even unintended low doses matter.

---

5. Imaging: The Hidden Risk You Often Overlook

Image-Guided Radiotherapy (IGRT) Doses Add Up

Imaging Type	Effective Dose	Problem
Cone-beam CT (pelvis)	22.7 mGy	Can reach cumulative >1 Gy with daily setup
Cone-beam CT (chest)	23.7 mGy	↑ SMN risk by 2-4% per imaging series
Repeat diagnostic CT	2+ Gy	Cumulative genotoxic burden

What to Do

• Prioritize non-ionizing imaging: MRI-guided radiotherapy or orthogonal kV imaging
• Minimize cone-beam CT frequency: Use sparingly; not daily if avoidable
• Avoid repeat diagnostic imaging: Use pre-treatment planning scans only
• Strongly consider: Whole-body MRI for surveillance instead of CT

---

6. Patient Selection: The Multidisciplinary Meeting

Before Recommending Radiotherapy, Discuss:

• TP53 variant class (dominant-negative → higher risk)
• Patient age (younger = longer exposure time for SMN development)
• Penetrance and personal cancer history (prior cancers = higher future risk)
• Tumor aggressiveness and prognosis
• Immediate oncologic risk vs. long-term SMN risk

Red Flags for Avoiding RT

• Early-stage, resectable cancer
• Long life expectancy (decades of SMN risk period)
• Favorable disease (e.g., FIGO stage IA ovarian cancer)

---

7. Reconstruction and Surgical Margins

Post-Operative Target Volume Strategy

If Reconstruction with Flap:

• Target volumes MUST include the flap-tissue interface
• Highest recurrence risk at native tissue/flap junction
• Use CTVs of 54-66 Gy as described

R1 Margin Status:

• If confirmed R1 margins → consider dose escalation to 66 Gy on R1 zone
• If R2 gross residual → 70 Gy discussed

---

8. Special Scenarios in Your Clinic

Breast Cancer (Most Common Question)

Scenario	Standard	Li-Fraumeni Approach
DCIS	Lumpectomy + RT	Mastectomy + reconstruction
Invasive, small	Lumpectomy + RT	Consider mastectomy; if RT needed → protons preferred
Invasive, N+ or advanced	Mastectomy + RT to chest wall	Accept RT need; use protons; minimize IGRT

Head & Neck Cancer

• Avoid IMRT if 3D achieves adequate coverage
• Proton therapy strongly preferred
• Non-ionizing image guidance (MRI) when possible

Pediatric Patients

• Highest risk for SMN (decades of follow-up remaining)
• Stricter avoidance:
• Adrenocortical CA: RT only for refractory/metastatic
• Choroid plexus tumors: Reduce/avoid RT; intensify chemotherapy
• Rhabdomyosarcoma: Avoid RT if resectable with favorable features

---

9. Practical Checklist for Your Next TP53 Patient

Before Starting Radiotherapy:

• Confirm TP53 mutation (class 4-5 or class 3)?
• Multidisciplinary discussion completed?
• Alternative non-RT curative option explored?
• Patient counseled on SMN risk AND blindness risk (optic nerve)?
• Dosimetry plan optimized for minimal low-dose bath?

During Treatment Planning:

• Proton therapy available and appropriate?
• If photons: 3D chosen over IMRT when feasible?
• IGRT protocol minimized?
• MRI guidance instead of CBCT planned?
• Normal tissue doses verified?

During Course:

• IGRT imaging kept to minimum necessary
• Patient weight stable (replanning if >3% change)
• Systematic surveillance protocol established post-RT

---

Key References from the Paper

• 30% of TP53 patients in one series developed 26 second malignancies within 10 years after radiotherapy
• Sarcomas most common SMN (often within 3 years of RT)
• Breast cancer patients aged 20-45 particularly high risk
• Proton therapy reduces SMN risk by factor of 2-10

---

Bottom Line for Your Practice

1. Avoid RT when possible → Surgery, surveillance, brachytherapy, immunotherapy
2. When RT unavoidable → Use protons if accessible; 3D photons if not
3. Minimize imaging doses → MRI guidance, fewer setup scans
4. Involve genetics/oncology team → No solo decision-making
5. Plan surveillance → Lifelong cancer screening warranted

---

This summary prioritizes the actionable, evidence-based recommendations most relevant to daily radiation oncology practice while acknowledging the underlying radiobiology complexity.